Amgen Inc. or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Amgen Inc. or Catalyst Pharmaceuticals, Inc.?

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Amgen Inc. and Catalyst Pharmaceuticals, Inc. have shown contrasting approaches. Amgen, a biotech giant, consistently reported SG&A expenses averaging around $5.3 billion annually from 2014 to 2023. In contrast, Catalyst Pharmaceuticals, a smaller player, maintained a leaner SG&A structure, with expenses averaging approximately $36.7 million annually.

A Decade of Financial Discipline
Amgen's SG&A expenses grew by about 31% over the decade, peaking in 2023. Meanwhile, Catalyst Pharmaceuticals saw a staggering increase of over 2,800% in the same period, reflecting its rapid growth and expansion strategy. This data highlights the different scales and strategies of these companies, offering insights into their operational efficiencies and market positioning.